- $145.19m
- $51.66m
- $138.90m
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview
Brief: Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Quanterix Announces Planned Transition Of Chief Financial Officer
Biomarker detection firm Quanterix reaffirms 2026 revenue guidance
Quanterix Q4 revenue rises 25%
Brief: Quanterix Announces FDA 510(K) Submission For A Multi-Analyte Algorithmic Blood Test For Alzheimer’S Disease Detection
Brief: Quanterix Appoints Everett Cunningham As President And CEO Effective January 19, 2026
Brief: Quanterix Announces Landmark Nature Study Redefining Alzheimer’S Disease Neuropathology Prevalence
Quanterix Q3 revenue rises on Alzheimer's diagnostics business
Brief: Quanterix Q3 Net Income USD -33.517 Million
Quanterix Corp reports results for the quarter ended June 30 - Earnings Summary
Brief: Quanterix Q2 Net Income USD -30.013 Million
Brief: Quanterix Announces Cooperation Agreement With Kent Lake Capital
Quanterix Corp expected to post a loss of 36 cents a share - Earnings Preview
Brief: Quanterix Terminates Executives Of Akoya Biosciences